Blood test may help overcome barriers to colon cancer screening

NCT ID NCT06444542

Completed Knowledge-focused Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study with 297 participants examined if offering a blood-based screening test (Guardant Shield) encourages people who previously avoided stool tests or colonoscopy to get screened for colorectal cancer. Participants were adults aged 45-75 at average risk who had not completed a recommended screening. The study measured their preference for the blood test and tracked how many chose it over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Guardant Shield blood-based colorectal cancer screening test
What this could lead to: If successful, this could show that a simple blood test boosts screening rates in people who avoid traditional methods, potentially catching more cancers early.
What could go wrong: This is a completed behavioral study, not a treatment trial. It measures preferences and adoption rates, not health outcomes, so it won't directly prove the test saves lives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLO-RECTAL CANCER

Contacts and locations

Locations

Penn State College of Medicine

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.